Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (37)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Monani, U. R.
Right arrow Articles by Burghes, A. H.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monani, U. R.
Right arrow Articles by Burghes, A. H.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2000, Vol. 9, No. 16 2451-2457
© 2000 Oxford University Press

Animal models of spinal muscular atrophy

Umrao R. Monani1, Daniel D. Coovert2 and Arthur H.M. Burghes1,2,+

1Department of Neurology, Means Hall, 1654 Upham Drive and 2Department of Molecular and Cellular Biochemistry, Hamilton Hall, 1645 Neil Avenue, The Ohio State University, Columbus, OH 43210, USA

Proximal spinal muscular atrophy (SMA) is the second most common autosomal recessive inherited disorder in humans. It is the most common genetic cause of infant mortality. As yet, there is no cure for this neuromuscular disorder which affects the lower motor neurons and proximal muscles of the limbs and trunk. In the last decade, significant advances have been made in understanding this disease, from linkage analysis to isolating the defective gene and identifying its protein product. This review summarizes the most recent advance in SMA research: the development of animal models of the disease, in particular mouse models of SMA. The SMA mice that we describe here present with symptoms similar to those seen in SMA patients. They promise to further the understanding of the molecular basis of this disease and demonstrate the feasibility of using the intact SMN2 gene, found in all SMA patients, as a means of treating this disorder.

+ To whom correspondence should be addressed at: 363 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA. Tel: +1 614 688 4759; Fax: +1 614 292 4118; Email: burghes.1@osu.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Sci Transl MedHome page
M. L. Hastings, J. Berniac, Y. H. Liu, P. Abato, F. M. Jodelka, L. Barthel, S. Kumar, C. Dudley, M. Nelson, K. Larson, et al.
Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy
Science Translational Medicine, November 4, 2009; 1(5): 5ra12 - 5ra12.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
J. Hauke, M. Riessland, S. Lunke, I. Y. Eyupoglu, I. Blumcke, A. El-Osta, B. Wirth, and E. Hahnen
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition
Hum. Mol. Genet., January 15, 2009; 18(2): 304 - 317.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
S Rudnik-Schoneborn, R Heller, C Berg, C Betzler, T Grimm, T Eggermann, K Eggermann, R Wirth, B Wirth, and K Zerres
Congenital heart disease is a feature of severe infantile spinal muscular atrophy
J. Med. Genet., October 1, 2008; 45(10): 635 - 638.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
T. W. Prior
Spinal Muscular Atrophy Diagnostics
J Child Neurol, August 1, 2007; 22(8): 952 - 956.
[Abstract] [PDF]

Home page
 Genome ResHome page
J. C. Fyfe, M. Menotti-Raymond, V. A. David, L. Brichta, A. A. Schaffer, R. Agarwala, W. J. Murphy, W. J. Wedemeyer, B. L. Gregory, B. G. Buzzell, et al.
An ~140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival
Genome Res., September 1, 2006; 16(9): 1084 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
F. Gabanella, C. Carissimi, A. Usiello, and L. Pellizzoni
The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation
Hum. Mol. Genet., December 1, 2005; 14(23): 3629 - 3642.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Hirtz, S. Iannaccone, J. Heemskerk, K. Gwinn-Hardy, R. Moxley III, and L. P. Rowland
Challenges and opportunities in clinical trials for spinal muscular atrophy
Neurology, November 8, 2005; 65(9): 1352 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
J. Jarecki, X. Chen, A. Bernardino, D. D. Coovert, M. Whitney, A. Burghes, J. Stack, and B. A. Pollok
Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy
Hum. Mol. Genet., July 15, 2005; 14(14): 2003 - 2018.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
E. C. Wolstencroft, V. Mattis, A. A. Bajer, P. J. Young, and C. L. Lorson
A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels
Hum. Mol. Genet., May 1, 2005; 14(9): 1199 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Majumder, S. Varadharaj, K. Ghoshal, U. Monani, A. H. M. Burghes, and S. T. Jacob
Identification of a Novel Cyclic AMP-response Element (CRE-II) and the Role of CREB-1 in the cAMP-induced Expression of the Survival Motor Neuron (SMN) Gene
J. Biol. Chem., April 9, 2004; 279(15): 14803 - 14811.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
K. Anderson, A. Potter, D. Baban, and K. E. Davies
Protein expression changes in spinal muscular atrophy revealed with a novel antibody array technology
Brain, September 1, 2003; 126(9): 2052 - 2064.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Ilangovan, W. L. Marshall, Y. Hua, and J. Zhou
Inhibition of Apoptosis by Z-VAD-fmk in SMN-depleted S2 Cells
J. Biol. Chem., August 15, 2003; 278(33): 30993 - 30999.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Rudnik-Schoneborn, H.H. Goebel, W. Schlote, S. Molaian, H. Omran, U. Ketelsen, R. Korinthenberg, D. Wenzel, H. Lauffer, M. Kreiss-Nachtsheim, et al.
Classical infantile spinal muscular atrophy with SMN deficiency causes sensory neuronopathy
Neurology, March 25, 2003; 60(6): 983 - 987.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Lefebvre, P. Burlet, L. Viollet, S. Bertrandy, C. Huber, C. Belser, and A. Munnich
A novel association of the SMN protein with two major non-ribosomal nucleolar proteins and its implication in spinal muscular atrophy
Hum. Mol. Genet., May 1, 2002; 11(9): 1017 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. Andreassi, J. Jarecki, J. Zhou, D. D. Coovert, U. R. Monani, X. Chen, M. Whitney, B. Pollok, M. Zhang, E. Androphy, et al.
Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients
Hum. Mol. Genet., November 1, 2001; 10(24): 2841 - 2849.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.